Breast Cancer Clinical Trial
Official title:
Phase I Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) Alone and in Combination With Docetaxel in Subjects With Advanced Solid Malignancies
Verified date | April 2009 |
Source | Threshold Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced solid tumors.
Status | Completed |
Enrollment | 50 |
Est. completion date | July 2008 |
Est. primary completion date | July 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Males and females, at least 18 years of age - Histologically confirmed, locally advanced or metastatic solid malignancy - Previously treated with at least one chemotherapy regimen for advanced or metastatic disease OR no curative standard treatment is available - Recovered from reversible toxicities of prior therapy - Life expectancy of at least 3 months - ECOG performance status of 0, 1, or 2 - Measurable or nonmeasurable disease by RECIST criteria - Ability to understand the purposes and risks of the study and having signed a written informed consent form - All women of childbearing potential and all men must agree to use effective means of contraception from entry into the study through 3 months after the last dose Exclusion Criteria: - Previous or current CNS metastases (screening CT or MRI is not required in asymptomatic subjects) - Active clinically significant infection requiring antibiotics - Known glucose-6-phosphate dehydrogenase deficiency or history of anemia of unknown etiology - History of clinically significant unexplained episodes of hypotension, fainting, dizziness, or lightheadedness - History or symptoms of cardiovascular disease, particularly coronary artery disease, arrhythmias, or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, or congestive heart failure - History of transient ischemic attack, stroke, or seizure disorder or any other CNS disease considered to be significant by the investigator - Known autonomic dysfunction or chronic orthostatic hypotension - Evidence of hypoglycemia, clinically significant renal disease, clinically significant liver disease (other than liver metastases), diabetes mellitus, gastrointestinal disorder (that could affect absorption or elimination of orally-administered medications), or obstructive uropathy with significant post-void residual during the past 5 years - Known HIV infection - Other primary malignancies (other than treated basal cell carcinoma of the skin or treated in situ cervical cancer) within the past 5 years - Major surgery within 4 weeks of the start of study treatment, without complete recovery - Antitumor therapy within 21 days of the start of study treatment - Disease progression/relapse on docetaxel therapy within the past 12 months - A history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 - Known sensitivity to methylparaben or propylparaben - Inability to discontinue prohibited medications for 24 hours before and after dosing on Day 1 of Weeks 1, 2, and 3 and Day 5 of Week 1. In addition, patients who cannot discontinue medications known to induce or inhibit CYP 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin, for the duration of the study are not eligible. - Peripheral neuropathy >= Grade 2 - Hemoglobin <9 g/dL - ANC <1500/µL - Platelet count <100,000/µL - Total bilirubin >1.5 mg/dL - Abnormal liver function - Serum creatinine >1.5 mg/dL unless creatinine clearance is >= 60 mL/min - Serum potassium < lower limit of normal - Elevated fasting blood glucose - Pregnant or nursing women - Participation in an investigational drug or device study within 28 days of the first day of dosing on this study - Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study. - Unwillingness or inability to comply with the study protocol for any other reason - Subjects who live alone |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Indiana University Cancer Center | Indianapolis | Indiana |
United States | University of Miami Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Institute for Drug Development Cancer Therapy & Research Center | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Threshold Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Significant Toxicity | |||
Primary | Disease Progression | |||
Secondary | Response Rate | |||
Secondary | Death |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |